GET DAILY SIGNALSPrecigen (PGEN) Turns Profitable in Q3 2026 with +37% QoQ PAPZIMEOS Growth
Key Takeaways
- Total revenue reached $74.1 million for the third quarter of 2026, up from $2.9 million in the year-ago period.
- PAPZIMEOS net product revenue grew 37% quarter-over-quarter to $72.9 million, driving a return to profitability.
- Net income was $35.8 million, or $0.08 per diluted share, versus a $325.3 million net loss a year earlier.
- The company achieved positive operating cash flow of $11.9 million a full quarter ahead of its year-end guidance.
- Reported EPS of $0.08 came in slightly below the $0.09 Zacks consensus estimate, while revenue narrowly missed the $74.15 million consensus.
- For more details on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- Discover fresh market opportunities with Trending AI Robots, which surface AI-driven trade ideas across stocks and ETFs.
Earnings Context and Why It Matters
Precigen (PGEN) is a commercial-stage biopharmaceutical company that has undergone a rapid financial transformation since the U.S. Food and Drug Administration approved its lead therapy, PAPZIMEOS, in August 2025. Once a pre-revenue developer of precision medicines, the company is now scaling a commercial launch in adult recurrent respiratory papillomatosis, a rare disease. The third quarter of 2026 marks a key checkpoint in that rollout. From what I see, investors are watching whether PAPZIMEOS demand is durable, whether margins hold near historically high levels, and whether the company can sustain the profitability and positive cash flow it has begun to generate. These results offer a direct read on the commercial strategy that now defines Precigen's investment story.
Reported Results
Precigen reported total revenue of $74.1 million for the three months ended September 30, 2026, an increase of roughly $71.2 million from the year-ago quarter. Net product revenue from PAPZIMEOS was $72.9 million, up 37% from the second quarter, while collaboration and licensing revenue declined by $1.8 million. Gross margin came in at approximately 91%, with cost of products and services of $6.5 million. Research and development expenses fell 46.4% year over year to $6.6 million, and selling, general, and administrative expenses declined 6.8% to $22.4 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On the bottom line, the company swung to net income of $35.8 million, or $0.10 per basic share and $0.08 per diluted share, compared with a net loss of $325.3 million, or $1.06 per share, in the prior-year period. Management highlighted that the company generated $11.9 million in cash from operating activities, reaching positive cash flow ahead of its year-end guidance. Cash and investments totaled $51 million at quarter-end. Reported earnings per share of $0.08 fell slightly short of the $0.09 consensus estimate, while revenue missed the consensus of $74.15 million by about 1.7%.
Market Reaction and Investor Sentiment
Heading into the release, sentiment around Precigen was broadly positive, driven by the rapid uptake of PAPZIMEOS and the company's move toward profitability. Precigen shares had gained roughly 25.6% year-to-date through the report, outpacing the broader market. The market's reaction to the third-quarter results will hinge on how investors weigh a modest shortfall against consensus estimates against the more important milestone of positive operating cash flow delivered ahead of schedule. The sequential 37% revenue growth signals that commercial demand continued to build, which may reassure investors focused on the durability of the launch rather than a single-quarter comparison against analyst forecasts.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching several factors that could shape Precigen's trajectory following this earnings report. First is the sustainability of PAPZIMEOS revenue growth. The therapy launched just over a year ago, and management expects continued momentum as adoption expands. Tracking new patient starts, physician adoption beyond academic centers, and payer access will be important signals of whether demand can keep accelerating.
Second is margin stability. Management has guided that gross margins on U.S. PAPZIMEOS sales should remain in the high-80s to low-90s range going forward. Any meaningful deviation from that band would be worth monitoring, as it would affect profitability and cash generation.
Third, the company's pipeline offers longer-term catalysts. Precigen is advancing a pediatric PAPZIMEOS program and a pipeline candidate, PRGN-2009, targeting HPV-related cancers, with late-2026 data readouts expected. These milestones could expand the company's addressable market beyond its current RRP franchise.
Finally, investors should keep an eye on the balance sheet and cash position. With positive operating cash flow now achieved and $96.5 million in trade accounts receivable expected to be collected over the months following quarter-end, the company's liquidity runway and its ability to fund further commercialization without additional dilution remain key considerations.
Using AI Tools to Track Biotech Opportunities
I often rely on Tickeron’s AI Screener when evaluating names like this after earnings. The tool lets me quickly filter for stocks showing similar patterns in revenue growth, margins, and cash flow trends, helping me compare Precigen against peers in the biotech space without spending hours on manual screens. It has become a regular part of my process for spotting ideas worth watching more closely.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PGEN in downward trend: price dove below 50-day moving average on October 15, 2026
PGEN moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend. In 33 of 36 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PGEN as a result. In 78 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for PGEN turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 43 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
The 10-day moving average for PGEN crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for PGEN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PGEN's RSI Oscillator exited the oversold zone, 25 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 67 of 70 cases where PGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +14.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in 206 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
PGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. PGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (41.534) is normal, around the industry mean (3.051). P/E Ratio (-4.724) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (32.258) is also within normal values, averaging (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
If I Want to Establish a Money Purchase/Profit Sharing Plan, Do I Have to Establish One for All Owners of My Business?
The Golden Rules of Investing: Navigating towards Profitable Returns
What is a Capital Account?
How Do You Analyze Mid-Cap Stocks to Find the Investment 'Sweet Spot' ?
What Is a Skilled Nursing Facility?
General Information
a biotechnology company, which engages in the research and development of synthetic biology technologies.
Industry Biotechnology
Advertisement